Kintara Announces Grant from Luxembourg National Research Fund and Cancer Foundation Luxembourg to Support VAL-083's Mechanism of Action Research in Glioblastoma
Summary
The grant is intended to support Dr. Golebiewskas research on the mechanism of action for VAL-083s utility to treat glioblastoma (GBM). Along with co-investigator Dr. Petr Nazarov, Ph.D., Dr. Golebiewskas research project is titled "Deconvolution of heterogeneity in the Glioblastoma cellular ecosystem for understanding treatment resistance and improving patient stratification (DIOMEDES)," and is based on complementary expertise in GBM biology and computational methods for the deconvolution of the complex biological systems associated with the disease. By combining state-of-the art preclinical models, transcriptomic analyses at the single and bulk cell level, and powerful deconvolution methods, the researchers aim to unravel mechanisms that shape treatment resistance in GBM. Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs. Kintara is also advancing its proprietary, late-stage photodynamic therapy platform that holds promise as a localized cutaneous, or visceral, tumor treatment as well as in other potential indications.